Tekmira Pharmaceuticals Presents Data on Improved Drug Delivery Technology at International RNAi Conference.(Conference news)

VANCOUVER, BRITISH COLUMBIA, Mar 28, 2008 (Marketwire via COMTEX) -- Tekmira Pharmaceuticals Corporation ("Tekmira") (TSX:TKM) announced today that a new second-generation formulation of the Company's liposomal drug delivery technology has the potential to bring a 10-fold increase in potency to RNA interference (RNAi) drugs that are administered intravenously.

The preclinical data are being presented at the "RNAi, MicroRNA, and Non-Coding RNA" Keystone Symposium held March 25-30, 2008 in Whistler, British Columbia.

RNAi drugs have the potential to treat ...